Cargando…
One drug to treat many diseases: unlocking the economic trap of rare diseases
There are two major problems with the development of therapies for rare diseases. First, among over 7000 such diseases, the vast majority are caused by genetic defects and/or include neurodegeneration, making them very difficult to treat. Second, drugs for rare diseases, so-called orphan drugs, are...
Autores principales: | Pierzynowska, Karolina, Kamińska, Teresa, Węgrzyn, Grzegorz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584527/ https://www.ncbi.nlm.nih.gov/pubmed/32926291 http://dx.doi.org/10.1007/s11011-020-00617-z |
Ejemplares similares
-
Complex Changes in the Efficiency of the Expression of Many Genes in Monogenic Diseases, Mucopolysaccharidoses, May Arise from Significant Disturbances in the Levels of Factors Involved in the Gene Expression Regulation Processes
por: Cyske, Zuzanna, et al.
Publicado: (2022) -
Ferroptosis and Its Modulation by Autophagy in Light of the Pathogenesis of Lysosomal Storage Diseases
por: Pierzynowska, Karolina, et al.
Publicado: (2021) -
How close are we to therapies for Sanfilippo disease?
por: Gaffke, Lidia, et al.
Publicado: (2017) -
Tubulin Cytoskeleton in Neurodegenerative Diseases–not Only Primary Tubulinopathies
por: Cyske, Zuzanna, et al.
Publicado: (2022) -
Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington’s disease patients
por: Pierzynowska, Karolina, et al.
Publicado: (2019)